Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
This study is ongoing, but not recruiting participants.
Sponsored by: Hadassah Medical Organization
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00801372
  Purpose

Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.


Condition
Pregnant, Healthy Females
Healthy Male Newborns

U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells

Further study details as provided by Hadassah Medical Organization:

Estimated Enrollment: 1
Study Start Date: November 2008
Groups/Cohorts
Pre-existing Fibroblast MCB
Pre-existing fibroblast donors for hESC derivation project

Detailed Description:

The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc.

The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.

pregnant healthy couples older than 18 who signed an informed consent for a c-section.

healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.

Criteria

Inclusion Criteria:

  • healthy, older than 18

Exclusion Criteria:

  • non healthy, younger than 18
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Publications:
Responsible Party: Hadassah Medical Organization ( Prof. Benjamin Reubinoff )
Study ID Numbers: HMO-0522-08
Study First Received: December 2, 2008
Last Updated: December 8, 2008
ClinicalTrials.gov Identifier: NCT00801372  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:
pregnant, healthy females older than 18 who signed an informed consent for the termination of the pregnancy.
pregnant healthy couples older than 18 who signed an informed consent for a c-section.
healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed an informed consent.

Study placed in the following topic categories:
Healthy

ClinicalTrials.gov processed this record on January 16, 2009